News | Radiation Therapy | October 06, 2016

New Data on Elekta's MR-Linac Presented at ASTRO 2016

Multiple presentations highlight clinical potential of MR-linac in a variety of cancers and demonstrate the need to address intra-session motion

October 6, 2016 — Elekta announced recently that its high-field magnetic resonance linear accelerator (MR-linac) was the focus of multiple presentations at the American Society for Radiation Oncology (ASTRO) 2016 Annual Meeting, held Sept. 25 – 28 in Boston. Additional abstracts presented by members of Elekta’s MR-linac Consortium also highlighted the need for adaptation of radiation therapy to address moving tumors and nearby organs during treatment sessions. Naturally occurring physiological movements currently limit the ability to conform the treatment to the target and increase exposure of radiation to healthy tissues.

Elekta’s MR-linac will integrate an advanced linear accelerator and a 1.5 Tesla magnetic resonance imaging (MRI) system. Combined, these systems will allow for simultaneous radiation therapy delivery and high-field MR tumor monitoring.

A joint session of ASTRO and the European Society for Radiation Oncology (ESTRO) highlighted the potential for adaptive imaging in radiation therapy during a session titled “In Room Adaptive Imaging with a Focus on MRI.”  Elekta’s MR-linac was featured in two presentations during this session:

  • “Linac-based MR Device”; Christopher Schultz, M.D., FACR, professor in the Department of Radiation Oncology at Froedert and Medical College of Wisconsin. This presentation discussed strategies for integrating MR-linac into current RT protocols and provided an overview of the development plan that the Elekta MR-linac Consortium is undertaking in order to generate the clinical, physics and quality control data that will be essential for developing and realizing the full clinical potential of MR-linac technology.
  • “MRI Linac: Physics Perspective”; Bas Raaymakers, Ph.D., professor in the Department of Radiotherapy at University Medical Center Utrecht. This presentation highlighted the potential to leverage the power of MR-linac technology to move from pre-treatment planning to online plan adaptation and, ultimately, to real-time plan adaptation. Raaymakers also discussed the need for novel quality assurance procedures for MR-linac devices, patients and workflow.

Additional key findings related to the MR-linac Consortium’s development of MR-linac presented at the conference include:

  • Abdominal organ motion is complex and can occur despite motion management strategies. Abstract #3708: “Complex Abdominal Organ Motion Assessed from MRI”; Eenas Omari, Ph.D., postdoctoral fellow in the Department of Radiation Oncology at Medical College of Wisconsin;
  • Substantially improves targeting and lowers radiation dose to normal breast tissue in patients undergoing pre-operative partial breast irradiation. Abstract #3695: “Dosimetric Feasibility of Pre-operative Partial Breast Irradiation in Prone Position Using MR-linac” ; Phil Prior, Ph.D., medical physicist in the Department of Radiation Oncology at Medical College of Wisconsin;
  • Clinically acceptable treatment plans for patients with locally advanced non-small cell lung cancer can be created. Abstract #3150: “Dosimetric Implications for Radical Radiotherapy on the MR-linac (MRL) in Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)”; Hannah Bainbridge, M.D., clinical fellow lung team, The Institute of Cancer Research, Sutton, United Kingdom, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom;
  • Online adaptive replanning is feasible for prostate cancer radiation therapy. Abstract #3639: “A Hybrid Adaptive Replanning Approach for Prostate SBRT”; Ozgur Ates, Ph.D., postdoctoral fellow in the Department of Radiation Oncology at Medical College of Wisconsin; and
  • An automated quality assurance (QA) tool can quickly identify contour errors from auto-segmentation and may have utility in online adaptive replanning. Abstract #3638 “Implementation of a Machine-learning Based Automatic Contour QA Tool for Online Adaptive Radiotherapy of Prostate Cancer” ; Jing Qiao Zhang, Ph.D., postdoctoral fellow in the Department of Radiation Oncology at Medical College of Wisconsin.


Several additional presentations described the potential for MR-linac and adaptive therapy to enable dose painting — the precise delivery of varying doses of radiation to specific regions within a tumor in order to account for differences in cell type, location and density from one part of the tumor to another.

Elekta’s MR-linac is a work in progress and not available for sale or distribution.

For more information:

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI
Technology | Magnetic Resonance Imaging (MRI) | November 15, 2018
Canon Medical Systems USA Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on its new...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...